Company profile
Bioventus Inc.
NASDAQ: BVS · Healthcare · Medical - Devices
#203 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
66BFH 79DQ 52GM 56SS 63
v0.1 · 65/100 weight · provisional
↑ Piotroski F, return on equity · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$576.3M
Rev growth YoY (TTM)
+1.5%
Net income (FY)
$22.7M
Employees
950
as of 2026-08-11
Market cap
$945.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$568.1M$568.1M2025
Net income$22.7M$22.7M2025
Operating income$54.0M$54.0M2025
Total assets$683.6M$683.6M2025
Liabilities$455.1M$455.1M2025
Equity$184.1M$184.1M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
U.S.88%
International12%
By geography
UNITED STATES88%
Non-US12%
The read
What is Bioventus Inc.’s revenue?
Bioventus Inc. booked $568.1M in FY2025 revenue, contracting 0.9% year over year — about the middle of the pack among Healthcare companies we track, at a 4.0% net margin.
Peers · Healthcare
Azenta, Inc.75B+Catalyst Pharmaceuticals, Inc.83B+Hinge Health, Inc.47DOrganogenesis Holdings Inc.65BAtriCure, Inc.84B+Mirum Pharmaceuticals, Inc.64CNeighbors
Durham →Key facts
CEORobert Claypoole
SectorHealthcare
IndustryMedical - Devices
HeadquartersDurham, NC
ExchangeNASDAQ: BVS
Employees950
IPO date2021-02-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.